IMPORTANCE Type 2 diabetes is associated with increased cardiovascular (CV) risk.
Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors
but have included limited numbers of patients with high CV risk and chronic kidney
disease.